Oral Paclitaxel Efficacy Safety and PK in Recurrent and Metastatic Breast Cancer

The requested reference [156c3d625a43d01f09a7f300654fb6fc8c36689c] no longer exists in our database. It has been replaced by the current reference: [78aa7070e86b3911a58cde072b2f3b7f6132c9fd]

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2018
The objective of this study is to evaluate the efficacy, safety and pharmacokinetics of DHP107 (Oral Paclitaxel, Korea brand name: Liporaxel®) compared to IV Paclitaxel in patients with Recurrent or Metastatic Breast Cancer.
Epistemonikos ID: 594a205de7560ddf54a9dbadb3d020a13fd66ba4
First added on: May 21, 2024